By Chris Wack
BioXcel Therapeutics shares were up 14% to $3.13 after the company reported positive overall survival data from its Phase 2 trial of BXCL701, an investigational oral innate immune activator, in combination with Keytruda.
The stock hit a 52-week low of $2.23 on Oct. 3 and is down 71% in the past 12 months.
The target patients in the trial had small cell neuroendocrine prostate cancer.
Evaluable patients with SCNC showed a median overall survival of 13.6 months and a 12-month survival rate of 56.5%, BioXcel said.
The Phase 2 trial is evaluating the safety and efficacy of BXCL701 in combination with Keytruda in men with SCNC.
Keytruda is Merck & Co.’s blockbuster cancer drug, used to treat a number of cancers.
Write to Chris Wack at [email protected]
Read the full article here